JPRN-UMIN000033311已完成未知
A Randomized, Open Label, Multi-center Trial of 24-week intervention with Designated Treatment Application for Essential Hypertension as compared with standard life-style modification therapy - A Randomized, Open Label, Multi-center Trial of 24-week intervention with Designated Treatment Application for Essential Hypertension
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 151
研究概览
简要总结
At the primary endpoint at week 24, HERB intervention did not reduce the mean change in 24-hour SBP by ABPM compared to the control group (adjusted difference: -0.66 mmHg, p = 0.78).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with severe hypertension, a history of secondary hypertension, cardiovascular / cerebrovascular events, etc.
研究者
相似试验
已完成
3 期
Phase III Insulin Add-On Asia Regional Program - STDiabetesNCT02096705AstraZeneca477
已完成
3 期
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years OldDiabetes Mellitus, Type 2NCT03199053AstraZeneca256
已完成
3 期
Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSDJPRN-jRCT2080222347Chugai Pharmaceutical Co., Ltd.85
Unknown
3 期
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 DiabetesType 2 Diabetes MellitusNCT03159052Jiangsu HengRui Medicine Co., Ltd.450
进行中（未招募）
1 期
A clinical trial to assess the efficacy and safety of aclidinium bromide 400 µg/formoterol fumarate 12 µg combination taken twice daily compared with each individual component (aclidinium bromide 400 µg twice daily and formoterol fumarate 12 µg twice daily) and tiotropium 18 µg once daily when administered to patients with stable chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2015-005444-33-HUAstraZeneca AB2,200